The present disclosure relates to fused tricyclic compounds of formula (I) or its tautomers, polymorphs, stereoisomers, prodrugs, solvate or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2A adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2A receptor. Such conditions include, but are not limited to, Parkinsons disease, restless leg syndrome, Alzheimers disease, neurodegenerative disorder, inflammation, wound healing, dermal fibrosis, nocturnal myoclonus, cerebral ischaemia, myocardial ischemia, Huntington's disease, multiple system atrophy, corticobasal degeneration, Wilson's disease or other disorders of basal ganglia which results in dyskinesias, post traumatic stress disorder, hepatic cirrhosis, sepsis, spinal cord injury, retinopathy, hypertension, social memory impairment, depression, neuroprotection, narcolepsy or other sleep related disorders, attention deficit hyperactivity disorder, drug addiction, post traumatic stress disorder and vascular injury and the like. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.L'invention concerne des composés tricycliques fusionnés de formule (I) ou leurs tautomères, polymorphes, stéréoisomères, promédicaments, solvates, des sels de qualité pharmaceutique ou des compositions pharmaceutiques les contenant, ainsi que des méthodes de traitement d'états et de maladies médiées par ces derniers, utilisés comme antagonistes du récepteur de l'adénosine A2A. [Formule ]. Les composés de ladite invention sont utiles dans le traitement, la prévention ou la suppression de maladies et de troubles susceptibles d'être améliorés par la médiation du récepteur de l'ad
